47 results on '"Memmi, Mirella"'
Search Results
2. Role of CACNA1C in Brugada syndrome: Prevalence and phenotype of probands referred for genetic testing
3. Identification of a SCN5A founder mutation causing sudden death, Brugada syndrome, and conduction blocks in Southern Italy
4. Abstract 15723: Risk Factors for Beta-Blockers Failure in Catecholaminergic Polymorphic Ventricular Tachycardia
5. Abstract 15666: Survival Benefit of Implantable Cardioverter Defibrillators in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
6. Abstract 15656: Genotype-Specific Natural History of Catecholaminergic Polymorphic Ventricular Tachycardia
7. Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19
8. Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome
9. Evidence of Carotid Atherosclerosis Vulnerability Regression in Real Life From Magnetic Resonance Imaging: Results of the MAGNETIC Prospective Study
10. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers
11. Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1
12. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation
13. FKBP12.6 Deficiency and Defective Calcium Release Channel (Ryanodine Receptor) Function Linked to Exercise-Induced Sudden Cardiac Death
14. Brugada syndrome and sudden cardiac death in children
15. Identical de novo mutation at the D4F104S1 locus in monozygotic male twins affected by facioscapulohumeral muscular dystrophy (FSHD) with different clinical expression
16. Efficacy and Limitations of Quinidine in Patients with Brugada Syndrome
17. Inherited Brugada and Long QT-3 Syndrome Mutations of a Single Residue of the Cardiac Sodium Channel Confer Distinct Channel and Clinical Phenotypes
18. CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases
19. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome
20. Mechanisms of [I.sub.Ks] suppression in LQT1 mutants
21. Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome
22. Arrhythmogenic Right Ventricular Cardiomyopathy
23. Challenges in Molecular Diagnostics of Channelopathies in the Next-Generation Sequencing Era: Less Is More?
24. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3
25. Novel Insight Into the Natural History of Short QT Syndrome
26. Clinical utility gene card for: Catecholaminergic polymorphic ventricular tachycardia (CPVT)
27. Abstract 2765: Natural History and Genetic Features of Short QT Syndrome
28. Abstract 2257: KCNJ2 Mutations in Patients Referred for Catecholaminergic Polymorphic Ventricular Tachycardia Gene Screening
29. Clinical Phenotype and Functional Characterization of CASQ2 Mutations Associated With Catecholaminergic Polymorphic Ventricular Tachycardia
30. Arrhythmogenesis in Catecholaminergic Polymorphic Ventricular Tachycardia
31. Multiple pathways for calcium handling abnormalities linking a novel CASQ2 mutation to ventricular arrhytmias and sudden death
32. Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
33. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia
34. Novel Arrhythmogenic Mechanism Revealed by a Long-QT Syndrome Mutation in the Cardiac Na + Channel
35. Mutations in the Cardiac Ryanodine Receptor Gene ( hRyR2 ) Underlie Catecholaminergic Polymorphic Ventricular Tachycardia
36. Mechanisms of I Ks suppression in LQT1 mutants
37. Concentrations of l-dopa in plasma and plasma ultrafiltrates
38. Novel Arrhythmogenic Mechanism Revealed by a Long-QT Syndrome Mutation in the Cardiac Na+ Channel.
39. Age-dependent Electrical Remodelling in R33Q Catecholaminergic Ventricular Tachycardia Knock-in Mouse Model
40. Nonmodifiable Risk Factors Predict Outcomes in Brugada Syndrome.
41. AB23-1: Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: Insights from a RyR2 R4496C knock-in mouse model
42. Novel perspectives on natural history and risk stratification for patients with Andersen Tawil syndrome type 1
43. Rare Genetic Variants and Long-Term Follow-Up in Patients With Idiopathic Ventricular Fibrillation
44. Validation of 2013 Diagnostic Criteria for Brugada Syndrome in a Cohort of 300 Individuals With Extensive Follow-Up
45. Natural History and Genetic Features of Short QT Syndrome
46. Abstract 16322: Rare Genetic Variants and Long-Term Follow-Up in Patients With Idiopathic Ventricular Fibrillation.
47. Clinical utility gene card for: Catecholaminergic polymorphic ventricular tachycardia (CPVT).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.